EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prevalence, Disease Onset and Clinical Outcome in Arginase 1 Deficiency: Cross‐Border Surveillance in Germany, Austria, and Switzerland

Svenja Scharre iD, Annette L Hess, Florian Gleich, Sven F Garbade iD, Patrik Feyh, Daniela Karall iD, Anna Baghdasaryan, Martina Huemer iD, Julia B Hennermann iD, Andreas Hahn, Martin Lindner, Gwendolyn Gramer iD und 8 weitere

Journal of Inherited Metabolic Disease · 2026

DOI: 10.1002/jimd.70210 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, 2026. Verfasst von Svenja Scharre und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department I, Division of Pediatric Neurology and Metabolic Medicine, Heidelberg University, Medical Faculty Heidelberg, Center for Pediatric and Ado…. Hauptthemen laut MEDLINE: Hyperargininemia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Immedica Pharma AB, Immedica Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Arginase 1 deficiency (ARG1‐D) is an ultra‐rare urea cycle disorder characterized by progressive spastic paraplegia, developmental delay, epilepsy, and episodic hyperammonemia. Evidence on prevalence and clinical presentation is scarce. Therefore, epidemiology and the phenotypical spectrum were assessed in Germany, Austria, and Switzerland (DACH region). We conducted a questionnaire‐based, cross‐sectional study of confirmed ARG1‐D patients in the DACH region. Patients were stratified into early‐diagnosed (newborn screening [NBS] or high‐risk family screening [HR]) and diagnosed after symptom onset. We evaluated clinical, biochemical, and therapeutic characteristics of individuals with confirmed ARG1‐D. Epidemiological prevalence estimates were derived using national population data. A total of 20 patients were identified (Germany: 12, Austria: 7, Switzerland: 1). Eight were diagnosed early (NBS: 4, HR: 4) and 12 after symptom onset. Symptomatically diagnosed patients (median age 11 years) presented with a broad range of clinical manifestations, specifically progressive spastic paraplegia (67%), epilepsy (58%), dystonia (46%), developmental delay (58%), and hepatopathy (50%). Median age at diagnosis was 35 months in symptomatic patients versus 1 month in early‐diagnosed patients ( p = 0.03). Estimated pediatric prevalence was 1:1042080 in the DACH region, with high regional differences. Hyperammonemia was reported in 72%. Enzyme therapy had been initiated in 21%; 2 patients underwent liver transplantation. ARG1‐D is a rare disease with a prevalence of approximately 1:1000000 individuals, and a complex and progressive clinical phenotype. Detection via NBS or HR allows early diagnosis and treatment initiation, potentially altering the clinical outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperargininemiaHumansSwitzerlandAustriaChildFemaleMalePrevalenceGermanyCross-Sectional StudiesChild, PreschoolAdolescentInfant, NewbornInfantNeonatal ScreeningEpilepsyArginasePhenotypeAge of Onset

Stichwörter der Autor:innen

Argininemiaarginase 1 deficiencyepidemiologyphenotypespastic paraplegiaurea cycle disorder

Substanzen

Arginase

Autor:innen und Institutionen

  • Department I, Division of Pediatric Neurology and Metabolic Medicine, Heidelberg University, Medical Faculty Heidelberg, Center for Pediatric and Adolescent Medicine, Heidelberg, Germany.
  • Division of Metabolic Diagnostics and Newborn Screening, Heidelberg University, Medical Faculty Heidelberg, Heidelberg, Germany.
  • Department for Pediatric and Adolescent Medicine, Clinic for Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria.
  • Division of General Pediatrics, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria.
  • Division of Metabolism and Children's Research Centre, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Department of Paediatrics, LKH Bregenz, Bregenz, Austria.

ORCID-Profile: Svenja Scharre, Sven F Garbade, Daniela Karall, Martina Huemer, Julia B Hennermann, Gwendolyn Gramer, Johannes Haeberle, Ulrike Muetze

Förderung

  • Immedica Pharma AB
  • Immedica Pharma

Zitieren

APA

Scharre, S., Hess, A. L., Gleich, F., Garbade, S. F., Feyh, P., Karall, D., Baghdasaryan, A., Huemer, M., Hennermann, J. B., Hahn, A., Lindner, M., Gramer, G., Luecke, T., Kleinelanghorst, N., Haeberle, J., Lotz-Havla, A. S., Hoffmann, G. F., Okun, J. G., Muetze, U., & Kölker, S. (2026). Prevalence, Disease Onset and Clinical Outcome in Arginase 1 Deficiency: Cross‐Border Surveillance in Germany, Austria, and Switzerland. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.70210

Vancouver

Scharre S, Hess AL, Gleich F, Garbade SF, Feyh P, Karall D, et al. Prevalence, Disease Onset and Clinical Outcome in Arginase 1 Deficiency: Cross‐Border Surveillance in Germany, Austria, and Switzerland. Journal of Inherited Metabolic Disease. 2026. doi:10.1002/jimd.70210

BibTeX
@article{Scharre2026,
  author = {Scharre, Svenja and Hess, Annette L and Gleich, Florian and Garbade, Sven F and Feyh, Patrik and Karall, Daniela and Baghdasaryan, Anna and Huemer, Martina and Hennermann, Julia B and Hahn, Andreas and Lindner, Martin and Gramer, Gwendolyn and Luecke, Thomas and Kleinelanghorst, Nils and Haeberle, Johannes and Lotz-Havla, Amelie S and Hoffmann, Georg F and Okun, Juergen G and Muetze, Ulrike and Kölker, Stefan},
  title = {Prevalence, Disease Onset and Clinical Outcome in Arginase 1 Deficiency: Cross‐Border Surveillance in Germany, Austria, and Switzerland},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2026},
  doi = {10.1002/jimd.70210}
}
Kostenlos starten →